Non-HDL C equals apolipoprotein B: except when it does not!

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Clinical Practice Guidelines

Background:

• National guidelines face critical decisions regarding the incorporation of apolipoprotein B (apoB) into clinical practice.
• Canada has adopted apoB, while Europe and America's decisions are pending.

Purpose of the Study:

• To evaluate the comparative utility of apoB versus non-high-density lipoprotein cholesterol (non-HDL C) in cardiovascular risk assessment and therapy guidance.
• To analyze the complexities and clinical implications of using apoB and non-HDL C as lipid markers.

Main Methods:

• Review of major epidemiological studies and clinical trials.
• Analysis of apoB and non-HDL C as predictors of vascular risk.
• Examination of marker performance in diverse clinical scenarios and individual patient assessments.

Main Results:

• Evidence suggests apoB is superior to LDL-C for risk assessment and therapy adequacy.
• The superiority of apoB over non-HDL C is debated, with non-HDL C acting as an indirect measure of LDL particle number.
• While group predictions may be similar, apoB offers greater predictive power in individual patients.
• Clinical circumstances exist where apoB and non-HDL C yield different treatment decisions.

Conclusions:

• Apolipoprotein B (apoB) and non-HDL cholesterol (non-HDL C) are comparable, except in specific clinical situations.
• apoB provides greater specificity in diagnosis and therapy, emphasizing individual patient care over group statistics.
• The incorporation of apoB into clinical lipidology enhances personalized patient management.